drug · small molecule

avutometinib potassium

Marketedupdated 2mo ago

by $VSTM Verastem, Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 9, 2027

217 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

Dec 29, 2042formulationUS 11873296
Dec 29, 2042formulationUS 12509450
Sep 11, 2040method-of-use (U-4205)US 11517573
Oct 29, 2038method-of-use (U-4196)US 11400090
Aug 21, 2029compositionUS 79281093.1y
Apr 17, 2028compositionUS 82474111.8y
Feb 9, 2027compositionUS 7897792217d

FDA exclusivities (1)

May 8, 2030NCENew Chemical Entity (5y)3.8y

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 50m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?